SCHEMBL12233269

SCHEMBL12233269

C#Cc1nc2c(c(=O)[nH]c(=O)n2CC)n1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
HSD17B10 Q99714 3/20 0.41
HPGD P15428 2/20 0.41
MAPT P10636 2/20 0.41
PDE4A P27815 4/20 0.41
ADORA2A P29274 4/20 0.41
PDE4B Q07343 4/20 0.41
PDE4C Q08493 4/20 0.41
PDE4D Q08499 4/20 0.41
CYP2C9 P11712 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 4/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
POLB P06746 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12233267 0.84 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2TDP1LMNAHTT
SCHEMBL12233273 0.79 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2TDP1LMNAHTT
SCHEMBL12233268 0.78 MAPK1 (0.53) ALDH1A1SMN1; SMN2TDP1LMNAHTT
SCHEMBL4623661 0.74 MEN1 (0.52) ALDH1A1SMN1; SMN2TDP1LMNAHTT
SCHEMBL12257513 0.73 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2TDP1LMNAHTT
SCHEMBL2537017 0.73 KDM4E (0.47) ALDH1A1SMN1; SMN2HTTHSD17B10HPGD
SCHEMBL6884105 0.72 MEN1 (0.49) ALDH1A1SMN1; SMN2TDP1LMNAHTT
SCHEMBL16199473 0.71 MAPT (0.44) ALDH1A1SMN1; SMN2HTTHPGDMAPT
SCHEMBL3227594 0.68 PDE4A (0.55) ALDH1A1SMN1; SMN2HSD17B10HPGDPDE4A
SCHEMBL5422889 0.67 GAA (0.51) ALDH1A1SMN1; SMN2TDP1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044061-B2 Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. UCB PHARMA GMBH (DE) 2011-10-25 US disclosed
US-20080221134-A1 8-ALKYNYLXANTHINES AND DERIVATIVES RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221134-A1 8-ALKYNYLXANTHINES AND DERIVATIVES SLC6A3, PARK7, SLC18A2 ALDH1A1 184/4885SMN1; SMN2 212/4885TDP1 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.